Matteo Vergati

1.9k total citations
32 papers, 1.4k citations indexed

About

Matteo Vergati is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Matteo Vergati has authored 32 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Molecular Biology and 11 papers in Immunology. Recurrent topics in Matteo Vergati's work include Immunotherapy and Immune Responses (11 papers), Cancer Immunotherapy and Biomarkers (8 papers) and PARP inhibition in cancer therapy (7 papers). Matteo Vergati is often cited by papers focused on Immunotherapy and Immune Responses (11 papers), Cancer Immunotherapy and Biomarkers (8 papers) and PARP inhibition in cancer therapy (7 papers). Matteo Vergati collaborates with scholars based in Italy, United States and Malaysia. Matteo Vergati's co-authors include Jeffrey Schlom, Kwong Y. Tsang, James L. Gulley, Lucio Tentori, Grazia Graziani, Ravi A. Madan, Philip M. Arlen, William L. Dahut, Diane J. Poole and James R. Wright and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Matteo Vergati

32 papers receiving 1.4k citations

Peers

Countries citing papers authored by Matteo Vergati

Since Specialization

Citations

This map shows the geographic impact of Matteo Vergati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matteo Vergati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matteo Vergati more than expected).

Fields of papers citing papers by Matteo Vergati

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matteo Vergati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matteo Vergati. The network helps show where Matteo Vergati may publish in the future.

Co-authorship network of co-authors of Matteo Vergati

This figure shows the co-authorship network connecting the top 25 collaborators of Matteo Vergati. A scholar is included among the top collaborators of Matteo Vergati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matteo Vergati. Matteo Vergati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer 2017 ·Current Medicinal Chemistry ·Matteo Vergati, Eriseld Krasniqi, Girolamo Del Monte, Silvia Riondino, (unknown), Fiorella Guadagni, Patrizia Ferroni, Mario Roselli	25
2	Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio 2014 ·International Journal of Cancer ·Patrizia Ferroni, Silvia Riondino, Vincenzo Formica, Vittore Cereda, (unknown), Francesca Farina, Maria Giovanna Valente, Matteo Vergati, Fiorella Guadagni, Mario Roselli	66
3	Up‐regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration‐resistant prostate cancer 2013 ·International Journal of Cancer ·Ngar‐Yee Huen, Alan Lap‐Yin Pang, Jo A. Tucker, TL Lee, Matteo Vergati, Caroline Jochéms, Chiara Intrivici, Vittore Cereda, Wai‐Yee Chan, Owen M. Rennert, Ravi A. Madan, James L. Gulley, Jeffrey Schlom, Kwong Y. Tsang	34
4	Impact of chemotherapy on activated protein C‐dependent thrombin generation—Association with VTE occurrence 2013 ·International Journal of Cancer ·Mario Roselli, Patrizia Ferroni, Silvia Riondino, Sabrina Mariotti, Anastasia Laudisi, Matteo Vergati, Francesco Cavaliere, Raffaele Palmirotta, Fiorella Guadagni	24
5	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial 2012 ·The Lancet Oncology ·Ravi A. Madan, Mahsa Mohebtash, Philip M. Arlen, Matteo Vergati, Myrna Rauckhorst, Seth M. Steinberg, Kwong Y. Tsang, Diane J. Poole, Howard L. Parnes, James R. Wright, William L. Dahut, Jeffrey Schlom, James L. Gulley	274
6	Perianal Paget's disease: a case report and literature review. 2012 ·PubMed ·Matteo Vergati, V. Filingeri, (unknown), Mario Roselli	5
7	Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells 2011 ·Vaccine ·Vittore Cereda, Matteo Vergati, Ngar‐Yee Huen, (unknown), Caroline Jochéms, Chiara Intrivici, James L. Gulley, David Apelian, Jeffrey Schlom, Kwong Y. Tsang	17
8	The Consequence of Immune Suppressive Cells in the Use of Therapeutic Cancer Vaccines and Their Importance in Immune Monitoring 2011 ·BioMed Research International ·Matteo Vergati, Jeffrey Schlom, Kwong Y. Tsang	10
9	Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination 2010 ·Cancer Immunology Immunotherapy ·Matteo Vergati, Vittore Cereda, Ravi A. Madan, James L. Gulley, (unknown), Connie J. Rogers, Kenneth W. Hance, Philip M. Arlen, Jeffrey Schlom, Kwong Y. Tsang	46
10	Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). 2010 ·Journal of Clinical Oncology ·Ravi A. Madan, Mahsa Mohebtash, Philip M. Arlen, Matteo Vergati, S. M. Steinberg, K. Y. Tsang, William L. Dahut, Jeffrey Schlom, James L. Gulley	23
11	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer 2009 ·Cancer Immunology Immunotherapy ·James L. Gulley, Philip M. Arlen, Ravi A. Madan, Kwong-Yok Tsang, Mary Pazdur, Lisa Skarupa, Jacquin Jones, Diane J. Poole, Jack P. Higgins, James W. Hodge, Vittore Cereda, Matteo Vergati, Seth M. Steinberg, Susan Halabi, Elizabeth C. Jones, Clara Chen, Howard L. Parnes, James R. Wright, William L. Dahut, Jeffrey Schlom	218
12	Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype 2006 ·Molecular and Cellular Endocrinology ·Grazia Graziani, Lucio Tentori, Alessia Muzi, Matteo Vergati, Giuseppe Tringali, Giacomo Pozzoli, Pierluigi Navarra	46
13	Inhibition of poly(ADP‐ribose) polymerase prevents irinotecan‐induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma 2006 ·The FASEB Journal ·Lucio Tentori, Carlo Leonetti, Marco Scarsella, Alessia Muzi, Emanuela Mazzon, Matteo Vergati, Olindo Forini, Rena G. Lapidus, Weizheng Xu, Annalisa Susanna Dorio, Jie Zhang, Salvatore Cuzzocrea, Grazia Graziani, (unknown)	74
14	Corticotropin-releasing hormone receptor-1 in human endometrial cancer 2006 ·Oncology Reports ·Grazia Graziani, Gabriella Ferrandina, Giacomo Pozzoli, Matteo Vergati, Alessia Muzi, Francesco Legge, Lucio Tentori, Giovanni Scambia, Pierluigi Navarra	14
15	Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide 2005 ·European Journal of Cancer ·Lucio Tentori, Carlo Leonetti, Marco Scarsella, Alessia Muzi, Matteo Vergati, Olindo Forini, Pedro Miguel Lacal, Federica Ruffini, Barry Gold, (unknown), Jie Zhang, Grazia Graziani	40
16	Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs 2005 ·International Journal of Oncology ·Lucio Tentori, Matteo Vergati, Alessia Muzi, Lauretta Levati, Federica Ruffini, Olindo Forini, Patrizia Vernole, Pedro Miguel Lacal, Grazia Graziani	29
17	Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice 2005 ·Journal of Clinical Oncology ·Rena G. Lapidus, Lucio Tentori, Grazia Graziani, Carlo Leonetti, Marco Scarsella, Matteo Vergati, Alessia Muzi, (unknown)	8
18	N3-Methyladenine Induces Early Poly(ADP-Ribosylation), Reduction of Nuclear Factor-κB DNA Binding Ability, and Nuclear Up-Regulation of Telomerase Activity 2004 ·Molecular Pharmacology ·Lucio Tentori, Olindo Forini, (unknown), Alessia Muzi, Matteo Vergati, Ilaria Portarena, Carla Amici, Barry Gold, Grazia Graziani	9
19	Inhibition of Telomerase Increases Resistance of Melanoma Cells to Temozolomide, but Not to Temozolomide Combined with Poly (ADP-Ribose) Polymerase Inhibitor 2003 ·Molecular Pharmacology ·Lucio Tentori, Ilaria Portarena, Marcella Barbarino, Alessandra Balduzzi, Lauretta Levati, Matteo Vergati, Annamaria Biroccio, Barry Gold, Maria Luisa Lombardi, Grazia Graziani	30
20	Valproic Acid Increases the Stimulatory Effect of Estrogens on Proliferation of Human Endometrial Adenocarcinoma Cells 2003 ·Endocrinology ·Grazia Graziani, Lucio Tentori, Ilaria Portarena, Matteo Vergati, Pierluigi Navarra	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact